 "Arogya Finance ties up with Dr Reddy's to provide cheaper Hep-C drug to patients")
The financial firm will facilitate easy equated monthly installments to patients to pay for the drug for Hepatitis C and a few other therapies provided by Dr Reddy's.
ALSO READ: 'Most Hepatitis C affected untreated in India'
Arogya Finance offers collateral free medical loan and makes it available within 24 hours for people traditionally unbankable among others while using a psychometric test as an innovative risk assessment tool to evaluate them.
ALSO READ: New HCV drugs are cheaper, much more effective: Dr Anil Arora
"According to World Health Organisation over 12 million people in India suffer from chronic Hepatitis C leading to unexpected healthcare expense burden. Arogya Finance in association with Dr Reddy's has taken an initiative to offer medical loans at reasonable terms and making it available at the right time, right place and reaching out to the patients in rural India. We are providing a one-stop financial solution for people in need whenever and where ever there is an unforeseen medical emergency,"said Jose Peter, co-founder and CEO of Arogya Finance.
ALSO READ: Natco, Hetero get drug regulator's nod for Gilead's Hep-C drug
Dr Reddy's will make available the chronic Hepatitis C medicine, Sofosbuvir 400 mg, which was being sold under the brand name Resof, to Arogya Finance at a lower price "While the market price of the medicine is Rs 1.2 lakh, we will be providing the same at Rs 96,000 to patients as part of this tie-up,"a spokesperson of Arogya Finance said.
